Burosumab

Phase 1UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)

Conditions

Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome

Trial Timeline

Jul 1, 2019 → Mar 1, 2023

NCT ID

NCT03993821

About Burosumab

Burosumab is a phase 1 stage product being developed by Ultragenyx Pharmaceutical for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). The current trial status is unknown. This product is registered under clinical trial identifier NCT03993821. Target conditions include Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS) were approved

Approved (7) Terminated (1) Active (12)

✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved

✅ONTAKEisaiApproved

✅MogamulizumabKyowa KirinApproved

✅Clopidogrel + TicagrelorAstraZenecaApproved

✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved

✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03993821	Phase 1	UNKNOWN	Jul 1, 2019	Mar 1, 2023	Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
NCT03581591	Phase 3	Completed	Jan 31, 2018	Dec 6, 2019	Hypophosphatemia

Competing Products

20 competing products in Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)

See all competitors

Product	Company	Stage	Hype Score
ONTAK (denileukin difitox, DAB389IL-2)	Eisai	Approved	43
ONTAK	Eisai	Approved	43
E7777 9 mcg/kg	Eisai	Phase 3	40
ONTAK	Eisai	Approved	43
Mogamulizumab	Kyowa Kirin	Approved	47
Mogamulizumab + Brentuximab vedotin	Kyowa Kirin	Phase 1	36
Mogamulizumab	Kyowa Kirin	Phase 2	39
KW-0761 + Vorinostat	Kyowa Kirin	Phase 3	40
Enzastaurin	Eli Lilly	Phase 2	35
Clopidogrel + Ticagrelor	AstraZeneca	Approved	43
Pembrolizumab	Merck	Phase 2	42
Comparator: vorinostat	Merck	Pre-clinical	26
Pembrolizumab	Merck	Phase 2	39
TR701 FA	Merck	Phase 2	35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Tulisokibart + Placebo	Merck	Phase 2	39
Aspirin + Ipilimumab + Pembrolizumab	Merck	Phase 2	35
Pembrolizumab + Mogamulizumab	Merck	Phase 2	42
TR-701 FA + Linezolid	Merck	Phase 3	40